MX2008011473A - El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. - Google Patents

El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.

Info

Publication number
MX2008011473A
MX2008011473A MX2008011473A MX2008011473A MX2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A
Authority
MX
Mexico
Prior art keywords
msh
nicotine
analogues
precursors
derivatives
Prior art date
Application number
MX2008011473A
Other languages
English (en)
Spanish (es)
Inventor
Arturo Solis Herrera
Original Assignee
Arturo Solis Herrera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008011473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arturo Solis Herrera filed Critical Arturo Solis Herrera
Priority to MX2008011473A priority Critical patent/MX2008011473A/es
Publication of MX2008011473A publication Critical patent/MX2008011473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
MX2008011473A 2006-05-08 2008-09-08 El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. MX2008011473A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2008011473A MX2008011473A (es) 2006-05-08 2008-09-08 El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/MX2006/000031 WO2007129879A1 (es) 2006-05-08 2006-05-08 EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA.
MX2008011473A MX2008011473A (es) 2006-05-08 2008-09-08 El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.

Publications (1)

Publication Number Publication Date
MX2008011473A true MX2008011473A (es) 2008-09-24

Family

ID=38667940

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011473A MX2008011473A (es) 2006-05-08 2008-09-08 El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.

Country Status (13)

Country Link
US (4) US20090197921A1 (cg-RX-API-DMAC7.html)
EP (4) EP2801359A3 (cg-RX-API-DMAC7.html)
JP (1) JP2009536193A (cg-RX-API-DMAC7.html)
KR (1) KR20130116374A (cg-RX-API-DMAC7.html)
CN (1) CN101437515B (cg-RX-API-DMAC7.html)
AU (1) AU2006343439B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0621650A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651580C (cg-RX-API-DMAC7.html)
DK (1) DK2801360T3 (cg-RX-API-DMAC7.html)
ES (1) ES2683323T3 (cg-RX-API-DMAC7.html)
MX (1) MX2008011473A (cg-RX-API-DMAC7.html)
NZ (1) NZ572366A (cg-RX-API-DMAC7.html)
WO (1) WO2007129879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20110206642A1 (en) * 2009-10-15 2011-08-25 Cohava Gelber Preventing obesity-related metabolic syndrome with melagonesis
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
KR20170043655A (ko) 2014-09-09 2017-04-21 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
WO2017178897A2 (en) * 2016-04-12 2017-10-19 Arturo Solis Herrera Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
CA2560756A1 (en) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation

Also Published As

Publication number Publication date
US20120270907A1 (en) 2012-10-25
CN101437515B (zh) 2016-04-20
EP2801360A2 (en) 2014-11-12
EP2801358A3 (en) 2015-03-04
EP2801359A3 (en) 2015-05-06
DK2801360T3 (en) 2018-07-23
US20090197921A1 (en) 2009-08-06
EP2801360A3 (en) 2015-03-04
CA2651580C (en) 2016-01-19
EP2801358A2 (en) 2014-11-12
US20160279116A1 (en) 2016-09-29
WO2007129879A1 (es) 2007-11-15
BRPI0621650A2 (pt) 2011-12-20
JP2009536193A (ja) 2009-10-08
ES2683323T3 (es) 2018-09-26
NZ572366A (en) 2012-02-24
US20160008347A1 (en) 2016-01-14
AU2006343439B2 (en) 2013-05-16
CA2651580A1 (en) 2007-11-15
EP2027860A1 (en) 2009-02-25
CN101437515A (zh) 2009-05-20
EP2801359A2 (en) 2014-11-12
KR20130116374A (ko) 2013-10-23
AU2006343439A1 (en) 2007-11-15
EP2801360B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
NL300728I1 (cg-RX-API-DMAC7.html)
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
TW200630327A (en) Substituted phenylalkanoic acids
TW200510373A (en) Substituted quinolin-4-ylamine analogues
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
ATE516366T1 (de) Regulierte aptamer-therapeutika
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
CL2023003211A1 (es) Uso de medicamentos en el tratamiento de enfermedades tumorales.
Zhou et al. Design and synthesis of nanofibers of self-assembled de novo glycoconjugates towards mucosal lining restoration and anti-inflammatory drug delivery
TW200621251A (en) Substituted biaryl quinolin-4-ylamine analogues
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
FG Grant or registration